Custom Peptide-Assay Development
We make peptides work.
From biomarker discovery through manufacturing-ready prototypes.
Peptide-based immunoassays offer significant advantages – precise epitope targeting, consistent synthesis, and cost-effective manufacturing. The challenge has always been making them work reliably at clinical-grade performance.
Our proprietary peptide augmentation technology delivers 10-fold improvement in signal-to-noise ratio compared to conventional peptide ELISAs, without the complexity and costs of traditional conjugation methods.
Why Custom Peptide-ELISA Development Matters
Precision Targeting
Single-epitope resolution enables discrimination between closely related immune responses that whole-protein methods miss. Target exactly the antibody signature you need.
Manufacturing Economics
Synthetic peptides are consistently manufactured at scale for a fraction of recombinant protein costs. Eliminate batch-to-batch variability and complex purification.
Clinical Performance
Our technology achieves the sensitivity and specificity required for diagnostic applications. Extremely low non-specific binding with reproducible results across sample types.
Intellectual Property
Epitope-specific markers create stronger patent positions than whole-protein approaches. We provide IP strategy guidance based on our international portfolio.
Our Technology Advantage
Patent-Pending Peptide Augmentation
Direct peptide modifications eliminate traditional conjugation chemistry and carrier proteins.
The result: dramatically increased sensitivity without the background noise that has historically limited peptide-based diagnostics.
Performance metrics
-
10-fold signal enhancement over standard peptide ELISA
-
Extremely low non-specific binding for clinical-grade specificity
-
Compatible with multiplexed formats and standard bead chemistries
-
Reproducible results across diverse sample types (serum, plasma, dried blood spot)
This technology powers our manufactured Helitope™ diagnostic and is available for collaborative development programs.
Complete Development Pipeline
-
Discovery Phase: High-density peptide microarrays, AI-guided epitope prediction, cross-reactivity analysis
-
Validation Phase: Iterative peptide optimisation, patient cohort testing, preliminary diagnostic accuracy assessment
-
Prototype Development: ELISA format conversion, marker optimisation, large-scale cohort validation
-
Manufacturing Transition: Technology transfer support, quality systems documentation, regulatory pathway guidance, research-use-only kit development
Proven Track Record: We've successfully navigated this entire pipeline with our Helitope™ gastric cancer risk diagnostic – from epitope discovery through international patent protection to manufactured test kits entering clinical validation.
Extended Capabilities
-
Epitope-specific monoclonal antibody development – From immunisation through clone selection and validation
-
Lateral flow assays – Point-of-care format development using validated peptide markers
-
Multiplexed bead arrays – High-throughput screening on microsphere platforms
-
Electrochemiluminescence – Ultra-sensitive detection for low-abundance targets
-
Companion diagnostics – Co-development of diagnostic tests alongside therapeutic programs
-
Global sales & distribution network – Integration pathways for market-ready diagnostics
Why Work With Us
Proven Commercial Success: Our Helitope™ diagnostic validates our ability to translate epitope discovery into manufactured products with international patent protection.
-
Technical Excellence: 10-fold sensitivity improvement, validated epitopes, with established protocols and automated workflows.
-
Complete Capabilities: From epitope mapping through ELISA optimisation to manufacturing partnerships – we handle the entire development pipeline.
-
IP Expertise: Strategic guidance based on our 20-country patent portfolio. Freedom-to-operate analysis and patent-focused assay design.
-
Rapid Turnaround: Established protocols minimise development timelines. Regular project updates and collaborative problem-solving.
-
Quality Infrastructure: Based at Harry Perkins Institute with access to world-class research facilities and clinical networks.
Ready to Develop Your Peptide-Assay?
Whether you're validating biomarkers, developing diagnostics, or optimising vaccine candidates, our peptide-assay platform can accelerate your programs.